FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385799056> ?p ?o ?g. }

• W4385799056 endingPage "e2328817" @default.
• W4385799056 startingPage "e2328817" @default.
• W4385799056 abstract "Loss of a previously effective response while still using adequate antidepressant treatment occurs in a relatively high proportion of patients with major depressive disorder (MDD); therefore, there is a need to develop novel effective treatment strategies.To assess the efficacy and safety of a single subanesthetic dose of esketamine in boosting the efficacy of oral antidepressants for treating fluctuating antidepressant response in MDD.This single-center, double-blind, midazolam-controlled pilot randomized clinical trial was conducted at Beijing Anding Hospital, Capital Medical University in China. The study enrolled participants aged 18 years and older with fluctuating antidepressant response, defined as patients with MDD experiencing fluctuating symptoms after symptom relief and stabilization. Patient recruitment was conducted from August 2021 to January 2022, and participants were followed-up for 6 weeks. Data were analyzed as intention-to-treat from July to September 2022.All participants in the esketamine-treated group received intravenous esketamine at 0.2 mg/kg in 40 minutes. Participants in the midazolam control group received intravenous midazolam at 0.045 mg/kg in 40 minutes.The primary outcome was the response rate at 2 weeks, defined as a 50% reduction in Montgomery-Åsberg Depression Rating Scale (MADRS). Secondary outcomes included response rate at 6 weeks, remission rates at 2 and 6 weeks, and change in MADRS and Clinical Global Impression-Severity score from baseline to 6 weeks; remission was defined by a MADRS score of 10 or lower.A total of 30 patients (median [IQR] age, 28.0 [24.0-40.0] years; 17 [56.7%] female) were randomized, including 15 patients randomized to midazolam and 15 patients randomized to esketamine; 29 patients completed the study. Response rates at 2 weeks were significantly higher in the esketamine-treated group than in the midazolam control group (10 patients [66.7%] vs 1 patient [6.7%]; P < .001). Participants treated with esketamine experienced significantly greater reduction in MADRS score from baseline to 2 weeks compared with those treated with midazolam (mean [SD] reduction, 15.7 [1.5] vs 3.1 [1.3]; P < .001). No serious adverse events were observed in this trial, and no psychotogenic effects and clinically significant manic symptoms were reported.This pilot randomized clinical trial found that a single subanesthetic dose of esketamine could boost the efficacy of oral antidepressants in treating fluctuating antidepressant response, with a good safety profile.Chinese Clinical Trial Registry Identifier: ChiCTR2100050335." @default.
• W4385799056 created "2023-08-15" @default.
• W4385799056 creator A5010510499 @default.
• W4385799056 creator A5010919318 @default.
• W4385799056 creator A5012477139 @default.
• W4385799056 creator A5016835731 @default.
• W4385799056 creator A5017353032 @default.
• W4385799056 creator A5018230988 @default.
• W4385799056 creator A5024762971 @default.
• W4385799056 creator A5030921116 @default.
• W4385799056 creator A5035282947 @default.
• W4385799056 creator A5041855727 @default.
• W4385799056 creator A5049681537 @default.
• W4385799056 creator A5070026014 @default.
• W4385799056 date "2023-08-14" @default.
• W4385799056 modified "2023-09-25" @default.
• W4385799056 title "Esketamine vs Midazolam in Boosting the Efficacy of Oral Antidepressants for Major Depressive Disorder" @default.
• W4385799056 cites W1748696538 @default.
• W4385799056 cites W1948877773 @default.
• W4385799056 cites W1964388294 @default.
• W4385799056 cites W1993556404 @default.
• W4385799056 cites W2008115074 @default.
• W4385799056 cites W2031683787 @default.
• W4385799056 cites W2046403378 @default.
• W4385799056 cites W2069138677 @default.
• W4385799056 cites W2083405172 @default.
• W4385799056 cites W2084249661 @default.
• W4385799056 cites W2091345949 @default.
• W4385799056 cites W2142779078 @default.
• W4385799056 cites W2153749174 @default.
• W4385799056 cites W2156078023 @default.
• W4385799056 cites W2204218248 @default.
• W4385799056 cites W2276151134 @default.
• W4385799056 cites W2548304375 @default.
• W4385799056 cites W2614068273 @default.
• W4385799056 cites W2730146128 @default.
• W4385799056 cites W2789034326 @default.
• W4385799056 cites W2811304329 @default.
• W4385799056 cites W2895197076 @default.
• W4385799056 cites W2898517662 @default.
• W4385799056 cites W2912654919 @default.
• W4385799056 cites W2935995671 @default.
• W4385799056 cites W2946661342 @default.
• W4385799056 cites W3015664064 @default.
• W4385799056 cites W3159074378 @default.
• W4385799056 cites W3201351307 @default.
• W4385799056 cites W3204219363 @default.
• W4385799056 cites W3208279447 @default.
• W4385799056 cites W3216344858 @default.
• W4385799056 cites W4246108751 @default.
• W4385799056 cites W4280588804 @default.
• W4385799056 cites W4290098820 @default.
• W4385799056 cites W4362519238 @default.
• W4385799056 doi "https://doi.org/10.1001/jamanetworkopen.2023.28817" @default.
• W4385799056 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37578792" @default.
• W4385799056 hasPublicationYear "2023" @default.
• W4385799056 type Work @default.
• W4385799056 citedByCount "0" @default.
• W4385799056 crossrefType "journal-article" @default.
• W4385799056 hasAuthorship W4385799056A5010510499 @default.
• W4385799056 hasAuthorship W4385799056A5010919318 @default.
• W4385799056 hasAuthorship W4385799056A5012477139 @default.
• W4385799056 hasAuthorship W4385799056A5016835731 @default.
• W4385799056 hasAuthorship W4385799056A5017353032 @default.
• W4385799056 hasAuthorship W4385799056A5018230988 @default.
• W4385799056 hasAuthorship W4385799056A5024762971 @default.
• W4385799056 hasAuthorship W4385799056A5030921116 @default.
• W4385799056 hasAuthorship W4385799056A5035282947 @default.
• W4385799056 hasAuthorship W4385799056A5041855727 @default.
• W4385799056 hasAuthorship W4385799056A5049681537 @default.
• W4385799056 hasAuthorship W4385799056A5070026014 @default.
• W4385799056 hasBestOaLocation W43857990561 @default.
• W4385799056 hasConcept C126322002 @default.
• W4385799056 hasConcept C138496976 @default.
• W4385799056 hasConcept C139719470 @default.
• W4385799056 hasConcept C142724271 @default.
• W4385799056 hasConcept C15744967 @default.
• W4385799056 hasConcept C162324750 @default.
• W4385799056 hasConcept C168563851 @default.
• W4385799056 hasConcept C204787440 @default.
• W4385799056 hasConcept C27081682 @default.
• W4385799056 hasConcept C2776000289 @default.
• W4385799056 hasConcept C2776814716 @default.
• W4385799056 hasConcept C2776867660 @default.
• W4385799056 hasConcept C2778000748 @default.
• W4385799056 hasConcept C2779144063 @default.
• W4385799056 hasConcept C2779177272 @default.
• W4385799056 hasConcept C2780051608 @default.
• W4385799056 hasConcept C2781161787 @default.
• W4385799056 hasConcept C42219234 @default.
• W4385799056 hasConcept C535046627 @default.
• W4385799056 hasConcept C71924100 @default.
• W4385799056 hasConcept C83849319 @default.
• W4385799056 hasConceptScore W4385799056C126322002 @default.
• W4385799056 hasConceptScore W4385799056C138496976 @default.
• W4385799056 hasConceptScore W4385799056C139719470 @default.
• W4385799056 hasConceptScore W4385799056C142724271 @default.
• W4385799056 hasConceptScore W4385799056C15744967 @default.

• next